SeaStar Medical Holding Corp

SeaStar Medical Holding Corp (Nasdaq: LMAO) is a publicly traded medical device company operating in the critical care and nephrology sector, focused on its proprietary Selective Cytopheretic Device technology for treating acute inflammatory conditions including acute kidney injury. The company went public through a business combination with LMF Acquisition Opportunities, Inc., a blank-check company sponsored by LMF Capital Group that completed its initial public offering in 2021. The merger closed in late 2022, with the combined entity retaining the LMAO ticker on Nasdaq. SeaStar Medical filed an 8-K with the SEC on August 12, 2026, marking continued regulatory activity as a post-combination public company. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time deal data on LMAO and thousands of other SPAC transactions.